Characteristics of patients with CR, PR, or SD > 6 months
| Age, y . | Sex . | Response to lenalidomide . | Cycles to best response, n . | Time to treatment failure, mo . | Cycles of lenalidomide, n . | Relapsed or refractory . | Prior therapies, n . | Prior XRT . | Prior transplantations . | Time to enrollment, mo* . | Histology . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 52 | Female | CR | 2 | 6 | 6 | Refractory | 2 | Yes | Auto | 5 | NS |
| 42 | Female | PR | 18 | NA | ≥ 43 | Refractory | 5 | Yes | Auto | 6 | NS |
| 31 | Male | PR | 6 | 12 | 12 | Refractory | 2 | Yes | Auto | 4 | NS |
| 48 | Male | PR | 2 | 13 | 12 | Refractory | 6 | Yes | Auto | 2 | NS |
| 37 | Male | PR | 2 | 6 | 6 | Refractory | 5 | Yes | Auto | 3 | NS |
| 32 | Male | PR | 4 | 4 | 4 | Relapsed | 4 | No | Auto+Allo | 12 | NOS |
| 25 | Female | PR | 4 | 8 | 8 | Relapsed | 5 | Yes | Auto | 9 | NS |
| 33 | Female | SD > 6 mo | 6 | 12 | 12 | Relapsed | 3 | Yes | Auto | 36 | MC |
| 25 | Female | SD > 6 mo | 6 | 30 | 30 | Refractory | 4 | Yes | Auto | 1 | NS |
| 50 | Male | SD > 6 mo | 6 | 17 | 17 | Refractory | 3 | No | Auto | 2 | MC |
| 33 | Female | SD > 6 mo | 6 | 8 | 8 | Relapsed | 4 | Yes | Auto | 3 | NS |
| 29 | Female | SD > 6 mo | 6 | 21 | 21 | Refractory | 3 | Yes | Auto | 10 | NS |
| Age, y . | Sex . | Response to lenalidomide . | Cycles to best response, n . | Time to treatment failure, mo . | Cycles of lenalidomide, n . | Relapsed or refractory . | Prior therapies, n . | Prior XRT . | Prior transplantations . | Time to enrollment, mo* . | Histology . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 52 | Female | CR | 2 | 6 | 6 | Refractory | 2 | Yes | Auto | 5 | NS |
| 42 | Female | PR | 18 | NA | ≥ 43 | Refractory | 5 | Yes | Auto | 6 | NS |
| 31 | Male | PR | 6 | 12 | 12 | Refractory | 2 | Yes | Auto | 4 | NS |
| 48 | Male | PR | 2 | 13 | 12 | Refractory | 6 | Yes | Auto | 2 | NS |
| 37 | Male | PR | 2 | 6 | 6 | Refractory | 5 | Yes | Auto | 3 | NS |
| 32 | Male | PR | 4 | 4 | 4 | Relapsed | 4 | No | Auto+Allo | 12 | NOS |
| 25 | Female | PR | 4 | 8 | 8 | Relapsed | 5 | Yes | Auto | 9 | NS |
| 33 | Female | SD > 6 mo | 6 | 12 | 12 | Relapsed | 3 | Yes | Auto | 36 | MC |
| 25 | Female | SD > 6 mo | 6 | 30 | 30 | Refractory | 4 | Yes | Auto | 1 | NS |
| 50 | Male | SD > 6 mo | 6 | 17 | 17 | Refractory | 3 | No | Auto | 2 | MC |
| 33 | Female | SD > 6 mo | 6 | 8 | 8 | Relapsed | 4 | Yes | Auto | 3 | NS |
| 29 | Female | SD > 6 mo | 6 | 21 | 21 | Refractory | 3 | Yes | Auto | 10 | NS |
Auto indicates autologous SCT; Allo, allogeneic SCT; NS, nodular sclerosis; MC, mixed cellularity; NOS, not otherwise specified; and NA, not applicable
Time to enrollment indicates the length of time between the last prior therapy and enrollment in the current study.